Short answer
Alector, Inc. (ALEC) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results cover the quarter ended June 30, 2026.
Alector, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results cover the quarter ended June 30, 2026
- Earnings press release furnished as Exhibit 99.1, containing the detailed financial results
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $3.3M, down from $7.9M, reflecting lower AL101 AD collaboration revenue
- Net loss narrowed to $23.0M, or $0.21 per share, from $30.5M, or $0.30
- Operating expense reductions: R&D $19.5M and G&A $8.3M, both down year over year after workforce reductions
- Cash, equivalents, and investments $172.8M versus $256.0M at December 31, 2025, with funding projected through 2027
- AL137 selected as lead anti-Aβ program, targeting IND submission Q1 2027 and first-in-human dosing by April 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alector, Inc. 8-K filings
Get the next ALEC 8-K as it lands
Follow ALEC for push alerts, or ask the research agent what this filing means.